Claritev (CTEV)
Market Price (3/17/2026): $17.69 | Market Cap: $292.4 MilSector: Health Care | Industry: Health Care Technology
Claritev (CTEV)
Market Price (3/17/2026): $17.69Market Cap: $292.4 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 12% | Weak multi-year price returns2Y Excs Rtn is -47%, 3Y Excs Rtn is -87% | Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 1581% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -67% | Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -3.5% | |
| Not cash flow generativeFCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1.3% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -102% | ||
| High stock price volatilityVol 12M is 105% | ||
| Key risksCTEV key risks include [1] unsustainable leverage and solvency concerns due to high debt and ongoing net losses, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 12% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -67% |
| Weak multi-year price returns2Y Excs Rtn is -47%, 3Y Excs Rtn is -87% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 1581% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -3.5% |
| Not cash flow generativeFCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1.3% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -102% |
| High stock price volatilityVol 12M is 105% |
| Key risksCTEV key risks include [1] unsustainable leverage and solvency concerns due to high debt and ongoing net losses, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Claritev (CTEV) stock has lost about 65% since 11/30/2025 because of the following key factors:
1. Disappointing Q4 2025 Earnings and Weak 2026 Revenue Guidance.
Claritev reported a Q4 2025 Earnings Per Share (EPS) of ($4.88), significantly missing analysts' consensus estimates of ($3.96) by ($0.92), representing a negative earnings surprise of 23.23%. Concurrently, the company provided 2026 revenue guidance of $980 million to $1 billion, indicating a modest 2% to 4% growth over 2025. This guidance was perceived as a "dramatic deceleration from Q4's 6.2% acceleration," leading to a reported 45% plummet in shares as investors reacted to "anemic growth prospects."
2. Significant Insider Selling Activity.
Prior to the specified period, on November 14, 2025, H&F Corporate Investors VIII, Ltd., a 10% owner, executed a substantial sale of 1,500,000 shares for $73,001,250 at an average price of $48.67 per share. This transaction, exceeding the $5 million threshold, likely contributed to a negative market sentiment and signaled a lack of confidence from a major stakeholder, influencing the stock's downward trend.
Show more
1. Disappointing Q4 2025 Earnings and Weak 2026 Revenue Guidance.
Claritev reported a Q4 2025 Earnings Per Share (EPS) of ($4.88), significantly missing analysts' consensus estimates of ($3.96) by ($0.92), representing a negative earnings surprise of 23.23%. Concurrently, the company provided 2026 revenue guidance of $980 million to $1 billion, indicating a modest 2% to 4% growth over 2025. This guidance was perceived as a "dramatic deceleration from Q4's 6.2% acceleration," leading to a reported 45% plummet in shares as investors reacted to "anemic growth prospects."
2. Significant Insider Selling Activity.
Prior to the specified period, on November 14, 2025, H&F Corporate Investors VIII, Ltd., a 10% owner, executed a substantial sale of 1,500,000 shares for $73,001,250 at an average price of $48.67 per share. This transaction, exceeding the $5 million threshold, likely contributed to a negative market sentiment and signaled a lack of confidence from a major stakeholder, influencing the stock's downward trend.
Show more
Stock Movement Drivers
Fundamental Drivers
The -67.4% change in CTEV stock from 11/30/2025 to 3/16/2026 was primarily driven by a -67.8% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3162026 | Change |
|---|---|---|---|
| Stock Price ($) | 54.07 | 17.60 | -67.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 951 | 965 | 1.5% |
| P/S Multiple | 0.9 | 0.3 | -67.8% |
| Shares Outstanding (Mil) | 16 | 17 | -0.3% |
| Cumulative Contribution | -67.4% |
Market Drivers
11/30/2025 to 3/16/2026| Return | Correlation | |
|---|---|---|
| CTEV | -67.4% | |
| Market (SPY) | -2.1% | 1.9% |
| Sector (XLV) | -4.2% | 16.0% |
Fundamental Drivers
The -74.5% change in CTEV stock from 8/31/2025 to 3/16/2026 was primarily driven by a -75.1% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 3162026 | Change |
|---|---|---|---|
| Stock Price ($) | 68.91 | 17.60 | -74.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 936 | 965 | 3.2% |
| P/S Multiple | 1.2 | 0.3 | -75.1% |
| Shares Outstanding (Mil) | 16 | 17 | -0.4% |
| Cumulative Contribution | -74.5% |
Market Drivers
8/31/2025 to 3/16/2026| Return | Correlation | |
|---|---|---|
| CTEV | -74.5% | |
| Market (SPY) | 4.0% | 13.1% |
| Sector (XLV) | 10.4% | 19.5% |
Fundamental Drivers
The -16.2% change in CTEV stock from 2/28/2025 to 3/16/2026 was primarily driven by a -17.4% change in the company's P/S Multiple.| (LTM values as of) | 2282025 | 3162026 | Change |
|---|---|---|---|
| Stock Price ($) | 20.99 | 17.60 | -16.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 931 | 965 | 3.7% |
| P/S Multiple | 0.4 | 0.3 | -17.4% |
| Shares Outstanding (Mil) | 16 | 17 | -2.2% |
| Cumulative Contribution | -16.2% |
Market Drivers
2/28/2025 to 3/16/2026| Return | Correlation | |
|---|---|---|
| CTEV | -16.2% | |
| Market (SPY) | 13.6% | 16.6% |
| Sector (XLV) | 2.7% | 8.5% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2023 to 3/16/2026| Return | Correlation | |
|---|---|---|
| CTEV | ||
| Market (SPY) | 75.1% | 16.6% |
| Sector (XLV) | 24.3% | 8.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CTEV Return | - | - | - | - | 104% | -60% | -20% |
| Peers Return | 39% | -22% | 31% | 10% | -1% | -20% | 24% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -3% | 77% |
Monthly Win Rates [3] | |||||||
| CTEV Win Rate | - | - | - | - | 45% | 33% | |
| Peers Win Rate | 70% | 37% | 60% | 48% | 53% | 20% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| CTEV Max Drawdown | - | - | - | - | -17% | -68% | |
| Peers Max Drawdown | -9% | -34% | -4% | -8% | -20% | -27% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -3% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TRI, SPGI, MCO, IQV, VRSK.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/16/2026 (YTD)
How Low Can It Go
CTEV has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -16.1% | -25.4% |
| % Gain to Breakeven | 19.1% | 34.1% |
| Time to Breakeven | 599 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -28.8% | -33.9% |
| % Gain to Breakeven | 40.4% | 51.3% |
| Time to Breakeven | 116 days | 148 days |
| 2018 Correction | ||
| % Loss | -15.8% | -19.8% |
| % Gain to Breakeven | 18.8% | 24.7% |
| Time to Breakeven | 326 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -40.6% | -56.8% |
| % Gain to Breakeven | 68.3% | 131.3% |
| Time to Breakeven | 1,100 days | 1,480 days |
Compare to TRI, SPGI, MCO, IQV, VRSK
In The Past
SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Claritev (CTEV)
MultiPlan Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers analytics-based services, which reduce medical costs through data-driven algorithms that detect claims over-charges and recommend or negotiate reimbursement; network-based services that reduce medical costs through contracted discounts with healthcare providers; and payment and revenue integrity services, which reduce medical costs by identifying and removing improper and unnecessary charges paid during the claim. It also provides health benefit plans, which features reference-based pricing and tools to engage health plan members and providers to make the use of benefits before and after care delivery. The company serves national insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, third party administrators, bill review companies, Taft-Hartley plans, and other entities that pay medical bills in the commercial healthcare, government, workers' compensation, and auto medical markets. MultiPlan Corporation was founded in 1980 and is headquartered in New York, New York.
AI Analysis | Feedback
Here are 1-3 brief analogies for Claritev (CTEV):
- It's like the FICO for medical claims, using data analytics to identify overcharges and ensure proper payments for health insurers.
- Imagine them as the Priceline for healthcare costs, negotiating discounts with providers on behalf of health plans and payers.
AI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
null
AI Analysis | Feedback
Travis Dalton
Chair, President and Chief Executive Officer
Appointed CEO in March 2024, Travis Dalton brings over 20 years of leadership experience in healthcare, focusing on improving patient and provider outcomes while reducing healthcare costs. Prior to joining Claritev, he served as General Manager and Executive Vice President of Oracle Health, where he held global responsibility for growth, delivery, support, and health client accounts across 32 countries. He also spent over two decades at Cerner, holding various leadership positions including Chief Client & Services Officer and President.
Douglas M. Garis
Executive Vice President, Chief Financial Officer
Douglas M. Garis leads Claritev's finance and accounting team, specializing in FP&A, corporate strategy, capital deployment, and financial operations, with over 15 years of experience in finance and global public markets. Before joining Claritev, he was the Chief Financial Officer of Oracle Health and Life Sciences (Oracle's largest vertical industry), and previously served as Head of FP&A at Cerner. His career began at PwC, and he held multiple financial leadership roles at Masonite International Corporation.
Jerome W. Hogge, III
Executive Vice President, Chief Operations Officer
Jerome W. Hogge, III is responsible for overseeing Claritev's day-to-day operations as the Executive Vice President and Chief Operations Officer.
Michael C. Kim
Executive Vice President, Chief Digital Officer
Michael C. Kim serves as the Executive Vice President and Chief Digital Officer, where he leads the AI and Data Science Department. He is responsible for guiding the company's AI and analytics strategy, as well as new product development and capabilities.
Carol H. Nutter
Senior Vice President, Chief People Officer
Carol H. Nutter is the Senior Vice President and Chief People Officer at Claritev, where she is tasked with developing, promoting, and executing the company's people strategy to support its current needs and future growth. She has more than 20 years of experience in leading human capital functions, with previous executive leadership roles at companies such as Optoro, Promontory Financial Group, and Booz Allen Hamilton.
AI Analysis | Feedback
Here are the key risks to Claritev's business:
- Financial Stability and Performance: Claritev faces risks related to its financial health, highlighted by a reported "new major risk" of negative shareholders' equity. Additionally, concerns exist regarding the company's ability to meet financial projections, with 2026 guidance reportedly falling short of prior expectations. A significant portion of its revenue, approximately 85%, is tied to volumes, introducing considerable uncertainty in forecasting and potentially impacting consistent financial performance.
- Regulatory and Policy Changes in the Healthcare Industry: Claritev operates exclusively within the highly regulated U.S. healthcare industry, providing cost management, payment, and revenue integrity solutions. Consequently, the company is significantly exposed to legislative, regulatory, or policy changes affecting healthcare providers, payers, claims processing, data privacy, or reimbursement models. Such changes could alter the demand for its services or impose new operational burdens.
- Technological Competitiveness and Innovation: Claritev's business model is built upon "data analytics and technology-enabled" solutions, including data-driven algorithms to detect claims overcharges and manage costs. A key risk is the potential for competitors to develop more advanced or efficient healthcare technology and data analytics solutions, or for Claritev's existing technologies to become outdated, thereby eroding its competitive advantage and market position.
AI Analysis | Feedback
nullAI Analysis | Feedback
Claritev (CTEV) Addressable Markets
Claritev (symbol: CTEV), formerly MultiPlan Corporation, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. Based on its core offerings, the addressable markets for its main products and services are in the United States.
U.S. Healthcare Analytics Market
The U.S. healthcare analytics market, which encompasses data analytics and AI-driven insights for cost management, is substantial and growing. Various estimates indicate its size and projected growth:
- In 2024, the market was estimated to be between USD 13.87 billion and USD 21.21 billion. It is projected to grow to approximately USD 44.13 billion to USD 67.48 billion by 2033, with a compound annual growth rate (CAGR) ranging from 12.76% to 12.8% from 2025 to 2033.
- Other projections estimate the U.S. healthcare analytics market at USD 26.34 billion in 2025, reaching around USD 152.03 billion by 2034, with a CAGR of 21.49% from 2025 to 2034. Another source predicts a market size of USD 60.85 billion in 2025, growing to USD 293.42 billion by 2034, at a CAGR of 19.1%.
U.S. Healthcare Payment Integrity Market
Claritev's payment and revenue integrity services operate within the U.S. healthcare payment integrity market, which is focused on reducing fraud, waste, and abuse in healthcare payments:
- The U.S. payment integrity market size was estimated at approximately USD 1.24 billion to USD 1.85 billion in 2024-2025. This market is projected to grow significantly to between USD 14.12 billion and USD 21.04 billion by 2034-2035, with a high CAGR of around 27.5% to 27.52%.
- Another estimate indicates the market was valued at USD 15.12 billion in 2025 and is projected to grow to USD 31.25 billion by 2031, at a CAGR of 12.86% from 2026 to 2031.
U.S. Healthcare Revenue Cycle Management Market
Claritev's solutions also contribute to the broader healthcare revenue cycle management sector, which involves managing the financial aspects of healthcare:
- The U.S. healthcare revenue cycle management market was estimated at USD 65.38 billion in 2025 and is projected to reach approximately USD 195.92 billion by 2035, expanding at a CAGR of 11.6% from 2026 to 2035.
Reference-Based Pricing (RBP)
Claritev provides health benefit plans that feature reference-based pricing. While a direct dollar market size for RBP is not readily available, its adoption and potential impact are significant within the U.S. employer-sponsored health plan market:
- Approximately 2% to 3% of employers were utilizing some form of RBP in their healthcare programs in 2019, with 7% to 11% considering it for 2021 and beyond.
- RBP is gaining traction as a cost-saving strategy, with the potential to reduce healthcare spending by as much as 20% to 30% for employers.
- Self-funded employer groups, which represent 65% of U.S. workers, are increasingly exploring RBP to manage rising healthcare costs. The U.S. group health insurance market size was estimated at USD 1.41 trillion in 2024.
AI Analysis | Feedback
Claritev (CTEV) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market dynamics:
- Accelerated AI Adoption and Technology Initiatives: Claritev's focus on accelerated AI adoption, cloud migration, and automation initiatives is anticipated to enhance product development, improve operational efficiency, and stabilize margins, ultimately supporting long-term cash flow and reinvestment potential.
- Expansion into International and Emerging Markets: The company aims to achieve sustainable revenue growth and broaden its market reach by expanding into international and emerging markets.
- Strategic Partnerships and Strong Client Renewals: Sustainable revenue growth is underpinned by strong client renewals and strategic partnerships. An example includes a strategic agreement with Kinetiq Health to integrate claims surveillance, diagnostic second-opinion services, and cost-intervention expertise into Claritev's BenInsights analytics platform.
- Growth of Existing and Newly Integrated Solutions: The integration of Kinetiq Health's services into Claritev's BenInsights platform is expected to drive growth by providing enhanced capabilities for identifying high-cost claims early, supporting diagnostic certainty, and reducing avoidable spending.
- Organic Growth from Increased Claim Volumes and Bookings: Claritev's 2026 revenue guidance projects an organic growth of 4–6% when adjusted for non-recurring revenue. This growth is supported by strong Q4 momentum and record bookings, indicating an increase in the volume of claims processed and services utilized by clients, which is a significant driver given that approximately 85% of its revenue is volume-tied.
AI Analysis | Feedback
Share Repurchases
- In February 2023, MultiPlan (now Claritev) announced a new share repurchase program authorizing up to $100 million of its Class A common stock through December 31, 2023.
- This $100 million share repurchase program was extended through December 31, 2024; by November 8, 2023, $13.1 million had been repurchased, leaving $86.9 million authorized.
- In February 2026, Claritev's Board of Directors approved a new $75 million, five-year share repurchase program, effective from January 1, 2026, through December 31, 2030, with an annual limit of $20 million.
Share Issuance
- In November 2025, affiliates of Hellman & Friedman conducted a public offering of 1.5 million shares of Claritev's Class A common stock at $51.50 per share; Claritev itself did not sell any shares and did not receive any proceeds from this offering.
- For the six months ended June 30, 2025, Claritev received $0.7 million from the issuance of common stock under an Employee Stock Purchase Plan.
Outbound Investments
- In 2023, MultiPlan (now Claritev) deployed $140.9 million for the acquisition of Benefits Science LLC (BST).
Capital Expenditures
- Claritev (as MultiPlan) reported capital expenditures (purchase of property and equipment) of $84.7 million in 2021, $20.9 million in 2022, and $24.5 million in 2023.
- The capital expenditure forecast for fiscal year 2025 was revised to between $165 million and $175 million.
- Expected capital expenditures for fiscal year 2026 are projected to be between $160 million and $170 million, primarily focused on investments in its digital platform and product development initiatives.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Is Claritev Stock Built to Withstand More Downside? | 11/14/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to CTEV.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
| 08312025 | CTEV | Claritev | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | -80.5% | -80.5% | -80.5% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 184.81 |
| Mkt Cap | 35.6 |
| Rev LTM | 7,597 |
| Op Inc LTM | 2,138 |
| FCF LTM | 2,034 |
| FCF 3Y Avg | 1,888 |
| CFO LTM | 2,652 |
| CFO 3Y Avg | 2,495 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.3% |
| Rev Chg 3Y Avg | 5.7% |
| Rev Chg Q | 7.6% |
| QoQ Delta Rev Chg LTM | 1.8% |
| Op Mgn LTM | 33.4% |
| Op Mgn 3Y Avg | 31.2% |
| QoQ Delta Op Mgn LTM | -0.4% |
| CFO/Rev LTM | 36.2% |
| CFO/Rev 3Y Avg | 35.1% |
| FCF/Rev LTM | 30.2% |
| FCF/Rev 3Y Avg | 29.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 35.6 |
| P/S | 7.1 |
| P/EBIT | 20.0 |
| P/E | 28.6 |
| P/CFO | 18.0 |
| Total Yield | 4.2% |
| Dividend Yield | 0.9% |
| FCF Yield 3Y Avg | 2.9% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 3.0% |
| 3M Rtn | -20.3% |
| 6M Rtn | -20.3% |
| 12M Rtn | -11.9% |
| 3Y Rtn | 1.2% |
| 1M Excs Rtn | 8.0% |
| 3M Excs Rtn | -17.4% |
| 6M Excs Rtn | -23.1% |
| 12M Excs Rtn | -33.0% |
| 3Y Excs Rtn | -71.9% |
Price Behavior
Price Behavior
| Market Price | $17.60 | |
| Market Cap ($ Bil) | 0.3 | |
| First Trading Date | 02/14/2020 | |
| Distance from 52W High | -75.8% | |
| 50 Days | 200 Days | |
| DMA Price | $21.79 | $20.29 |
| DMA Trend | down | down |
| Distance from DMA | -19.2% | -13.3% |
| 3M | 1YR | |
| Volatility | 126.6% | 105.2% |
| Downside Capture | 180.09 | 138.76 |
| Upside Capture | -264.53 | 99.09 |
| Correlation (SPY) | 0.1% | 16.1% |
CTEV Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.58 | 0.02 | 0.64 | 1.49 | -0.01 | -0.96 |
| Up Beta | -3.66 | -1.47 | 0.13 | -0.47 | 1.43 | 0.16 |
| Down Beta | -1.27 | 1.57 | 1.80 | 4.47 | 1.26 | 1.01 |
| Up Capture | -476% | -424% | -318% | -118% | 55% | 7% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 8 | 16 | 26 | 57 | 128 | 128 |
| Down Capture | 425% | 348% | 332% | 219% | 119% | 76% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 13 | 25 | 35 | 66 | 118 | 118 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CTEV | |
|---|---|---|---|---|
| CTEV | -23.6% | 104.1% | 0.24 | - |
| Sector ETF (XLV) | 6.4% | 17.5% | 0.20 | 10.0% |
| Equity (SPY) | 22.5% | 18.9% | 0.94 | 17.0% |
| Gold (GLD) | 68.7% | 26.2% | 1.98 | -10.1% |
| Commodities (DBC) | 19.7% | 17.3% | 0.91 | -4.1% |
| Real Estate (VNQ) | 9.3% | 16.2% | 0.37 | 9.8% |
| Bitcoin (BTCUSD) | -9.2% | 44.2% | -0.09 | 15.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CTEV | |
|---|---|---|---|---|
| CTEV | -5.9% | 103.8% | 0.21 | - |
| Sector ETF (XLV) | 7.5% | 14.5% | 0.33 | 9.2% |
| Equity (SPY) | 13.1% | 17.0% | 0.60 | 17.3% |
| Gold (GLD) | 23.6% | 17.2% | 1.12 | -9.4% |
| Commodities (DBC) | 11.2% | 19.0% | 0.47 | -3.4% |
| Real Estate (VNQ) | 4.9% | 18.8% | 0.16 | 8.7% |
| Bitcoin (BTCUSD) | 6.1% | 56.7% | 0.33 | 17.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CTEV | |
|---|---|---|---|---|
| CTEV | -3.0% | 103.8% | 0.21 | - |
| Sector ETF (XLV) | 10.1% | 16.5% | 0.50 | 9.2% |
| Equity (SPY) | 14.7% | 17.9% | 0.70 | 17.3% |
| Gold (GLD) | 14.4% | 15.6% | 0.76 | -9.4% |
| Commodities (DBC) | 8.4% | 17.6% | 0.39 | -3.4% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.24 | 8.7% |
| Bitcoin (BTCUSD) | 67.9% | 66.8% | 1.07 | 17.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/23/2026 | -41.6% | -37.9% | |
| 11/7/2025 | 11.8% | -28.7% | -45.1% |
| 8/6/2025 | 29.4% | 66.2% | 71.2% |
| 5/8/2025 | 1.6% | 26.5% | 86.3% |
| SUMMARY STATS | |||
| # Positive | 3 | 2 | 2 |
| # Negative | 1 | 2 | 1 |
| Median Positive | 11.8% | 46.4% | 78.8% |
| Median Negative | -41.6% | -33.3% | -45.1% |
| Max Positive | 29.4% | 66.2% | 86.3% |
| Max Negative | -41.6% | -37.9% | -45.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/26/2026 | 10-K |
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 02/26/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/02/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/29/2024 | 10-K |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Dalton, Travis | Pres., CEO & Executive Chair | Spouse's Individual Retirement Account | Buy | 11202025 | 47.23 | 5,290 | 249,842 | 452,077 | Form |
| 2 | Mintz, William B | SVP, Chief Strategy Officer | Direct | Buy | 11192025 | 38.00 | 916 | 34,808 | 2,482,350 | Form |
| 3 | Kim, Michael | EVP, Chief Digital Officer | Direct | Buy | 11182025 | 38.25 | 9,600 | 367,199 | 4,036,474 | Form |
| 4 | O'Neil, Tara | SVP, General Counsel | Direct | Buy | 11182025 | 38.84 | 625 | 24,273 | 971,997 | Form |
| 5 | H&f, Corporate Investors Viii, Ltd | See Footnotes | Sell | 11142025 | 48.67 | 1,500,000 | 73,001,250 | 434,698 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.